Description: U.S. Stem Cell, Inc., formerly Bioheart, Inc., is a biotechnology company. The Company is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its MyoCell is a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. Its AdipoCell is a cell therapy with multiple possible treatment applications using autologous adipose cells. Its business includes the development of cell therapy products, as well as physician and patient-based regenerative medicine/cell therapy training services, and the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. It operates through divisions, including US Stem Cell Training, Vetbiologics and US Stem Cell Clinic.
Home Page: www.us-stemcell.com
1560 Sawgrass Corporate Parkway
Sunrise,
FL
33323
United States
Phone:
954 835 1500
Officers
| Name | Title |
|---|---|
| Mr. Michael Tomas | CEO, Pres, CFO & Director |
| Dr. Colleen Robb | Sr. Compliance Officer |
| Mr. Phil Posa | Sr. VP of U.S. & International Sales |
| Ms. Evelyn Flores | Corp. Controller |
| Dr. Sergio Pinski | Medical Director & Member of Scientific Advisory Board |
| Mr. James L. Greene | Clinical Operations Consultant |
| Fabianne Gershon | Consultant |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 30.362 |
| IPO Date: | 2008-02-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |